Advertisement
Product › Details
BGB324 (BerGenBio)
Next higher product group | AXL kinase inhibior (AXL inhibitor) | |
Status | 2011-10-31 development pp existent | |
Organisation | BerGenBio ASA (OSE: BGBIO) | |
Organisation 2 | Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) | |
Record changed: 2023-07-10 |
Advertisement
More documents for cancer drug
- [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [2] Alterome Therapeutics, Inc.. (4/3/24). "Press Release: Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives". San Diego, CA....
- [3] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
- [4] Ipsen S.A.. (4/2/24). "Press Release: Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting solid tumors". Paris & San Francisco, CA....
- [5] Eisbach Bio GmbH. (3/21/24). "Press Release: Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors". Martinsried & Houston, TX....
- [6] Angelini Ventures S.p.A.. (3/21/24). "Press Release: Angelini Ventures Invests into Extended €75.8 Million ($82 Mmillion) Series C Financing Round for Nouscom". Rome....
- [7] Tubulis GmbH. (3/14/24). "Press Release: Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline". Munich....
- [8] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....
- [9] Affimed N.V.. (3/6/24). "Press Release: Affimed Announces 1-for-10 Reverse Stock Split". Mannheim....
- [10] Tubulis GmbH. (3/5/24). "Press Release: Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024". Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top